Skip to content

The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat.

Z Abdul-Monim, G P Reynolds, J C Neill

Journal of psychopharmacology (Oxford, England) March 1, 2003 DOI: 10.1177/0269881103017001700 via PubMed

Summary

AI-generated from the abstract

The drug phencyclidine (PCP) induces schizophrenia-like symptoms in rats, including cognitive deficits. This study tested whether the antipsychotics ziprasidone or haloperidol could reverse a PCP-induced learning impairment in rats housed either in social isolation or in groups. PCP at 1.0 and 1.5 mg/kg impaired performance on a reversal learning task in both groups. Haloperidol did not reverse this impairment and at higher doses (0.1 and 0.25 mg/kg) worsened performance, especially in socially housed rats. Ziprasidone at 2.5 mg/kg reversed the PCP-induced deficit, significantly in social animals and non-significantly in isolates. Rearing conditions did not affect the deficit or drug responses.

Study at a glance

Characteristics Experimental study Peer reviewed
Sample size 50
Population Male rats (socially isolated or group-housed from weaning)
Interventions Phencyclidine Haloperidol Ziprasidone
Dose 1.0 and 1.5 mg/kg PCP; 0.05, 0.1, and 0.25 mg/kg haloperidol; 2.5 mg/kg ziprasidone
Key finding Ziprasidone, but not haloperidol, reversed the reversal learning deficit induced by PCP in rats.

Abstract

The glutamate/N-methyl-D-aspartate receptor antagonist phencyclidine (PCP) has been shown to induce both positive and negative symptoms of schizophrenia, as well as cognitive deficits, thus providing a relatively valid model of psychosis. Isolation rearing from weaning in the rat has been proposed as a non-pharmacological model of psychosis. The aim of the present study was to explore the validity of a combination of these techniques to model cognitive dysfunction associated with schizophrenia. The present study evaluates the effects of the novel antipsychotic ziprasidone and the typical antipsychotic haloperidol in their ability to reverse the cognitive deficit induced by PCP in isolation reared rats and social controls. Rats housed in social isolation (n = 25) or in groups of five (n = 25) from weaning were food deprived and trained to respond for food in an operant reversal learning paradigm. PCP at 1.0 and 1.5 mg/kg (intraperitoneally, i.p.) significantly and selectively impaired reversal task performance in both groups of rats. This impairment was not significantly improved following the coadministration of haloperidol (0.05 mg/kg, i.p.). Higher haloperidol doses (0.1 and 0.25 mg/kg, i.p.) were found to impair task performance, with the social animals being more sensitive than isolation-reared animals. In contrast, ziprasidone (2.5 mg/kg, i.p.) reversed the impairment caused by PCP. This was significant in social animals, while in isolates there was a non-significant enhancement in performance of the reversal task with ziprasidone compared to PCP alone. Thus, PCP produced a selective reversal learning deficit in rats, which was ameliorated following treatment with ziprasidone but not haloperidol. Rearing conditions did not influence performance of the test or the deficit produced by PCP.

Comments

No comments yet.

Log in to comment